📣This week's #podcast on #Recurrence rates and patterns in stage IA #p53abn #endometrial cancer by Drs Jessica Mcalpine and Amy Jamieson
Amy Jamieson Gynecologic Cancer Initiative

📌 bit.ly/4aNGJtE

Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes René Pareja Luis Chiva…

Interesting data on subgroups of high risk NSMP EC presented by ⁦Andrea Neilson⁩ at #AACRec23

Now we are joined by Dr. Amy Jamieson, who is discussing an exciting #vulvarcancer intervention tool!

3 recently identified molecular subtypes of vulvar squamous cell carcinoma and their ability to better predict response to radiation and expanse of surgery 🔬

Thanks Nanda Horeweg - excited to share the results of this Canadian and PORTEC collaboration

Can low grade endometrial cancer be p53 abnormal? Does the p53abn status matter for prognosis? Largest & most comprehensive study now in CCR: Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas aacrjournals.org/clincancerres/…

Check out our recent publication on Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.
UBC Pathology Gynecologic Cancer Initiative
#gynpath
onlinelibrary.wiley.com/doi/10.1111/hi…

Another golden apple from the PORTEC tree: read our latest paper in JCO on differences in radiotherapy response across the 4 molecular classes of endometrial cancer. Molecular testing can guide adjuvant therapy decisions, even in stage I endometrioid EC.

ascopubs.org/doi/10.1200/JC…

Excited to share findings from ProMisE NGS: a single-test DNA-based alternative to the original ProMisE classifier and was highly concordant and maintained prognostic significance.
@GynOncJnls
Gynecologic Cancer Initiative

sciencedirect.com/science/articl…

The molecular classification of endometrial cancer improves prognostication and reduces over- and undertreatment. We developed QPOLE, a simple & cheap alternative for POLE Sequencing by
qPCR. Implement it now —> details in our JCO GO publication: ascopubs.org/doi/10.1200/GO…

OBGYN Academic Day 2023 Award Winners - obgyn.ubc.ca/obgyn-academic…

Great to see the brightest and best ⁦BC Cancer⁩ coming through the ⁦CCTG⁩ practicum program ⁦Alannah Smrke⁩ ⁦Maryam Soleimani MD⁩ future is bright 💡 #CCTG2023

A clinical trial led by Dr. Yvette Drew, B.C. Cancer Medical Oncologist explores the efficacy of placing PARP inhibitors prior to chemotherapy or surgery as part of treatment for individuals with stage 4 high-grade serous ovarian cancer.

🔗 Read more: ovariancanada.org/clinical-trial…

Check out this powerful article on how the BC health system continues to fail individuals with gynecologic cancers ⏩: bit.ly/3ZruP2G

Thanks @GynOncJnls for allowing us to share our findings: Chemo was associated with longer DSS in p53abn EC, including stage I and non-serous histotypes. Chemo was not associated with improved outcomes in MMRd EC, even in stage III disease. gynecologiconcology-online.net/article/S0090-…

Fantastic work by this international group led by Dr McAlpine.

*⃣ Adjuvant chemo and RT associated with ⬆️DSS for patients with p53abn EC, including non-serous ECs.
*⃣ Chemo ≠ improved outcomes in MMRd EC, even in stage III disease.

pubmed.ncbi.nlm.nih.gov/36753816/

📢It is #WorldCancerDay today!
Join our editor-in-chief Pedro T Ramirez in our commitment to increase awareness, prevention and treatment for #gynaecological cancers worldwide!
#CloseTheCareGap #WCD2023
Andreina Fernandes Aarthi S Jayraj Ane Gerda Z Eriksson MD PhD IJGC Fellows

Endometrial cancer risk stratification within the No Specific Molecular Profile (NSMP) subtype International Society of Gynecologic Pathologists Amy Jamieson University of British Columbia SGO The Society of Gynecologic Oncology of Canada IGCS ESGO OncoAlert ASCO ESMO - Eur. Oncology sciencedirect.com/science/articl…

Thank you The New York Times for sharing about #opportunisticsalpingectomies , the first ever preventative treatment for #ovariancancer . What a pleasure to see quotes from our very own Dr. Dianne Miller!

Read the article here ⏩: nyti.ms/3kZSMzd